Evidence map›Paper›PMID 39335099›Full record

ArticleCancers2024

Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer.

Yuta Yamanaka, Takayo Ota, Yutaka Masuoka, Yuki Takeyasu, Satoaki Nakamura, Masaaki Terashima, Hiroshige Yoshioka, Masahiro Fukuoka, Takayasu Kurata

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuta YamanakaDepartment of Thoracic Oncology, Kansai Medical University Hospital, 2-5-1 Shinmachi, Hirakatashi 573-1010, Osaka, Japan.ORCID 0009-0009-7872-4395
Takayo OtaMedical Oncology, Izumi City General Medical Center, 4-5-1 Wakechou, Izumishi 594-0073, Osaka, Japan.ORCID 0000-0003-1630-8301
Yutaka MasuokaDepartment of Radiology, Izumi City General Medical Center, 4-5-1 Wakechou, Izumishi 594-0073, Osaka, Japan.ORCID 0000-0002-6926-2450
Yuki TakeyasuDepartment of Thoracic Oncology, Kansai Medical University Hospital, 2-5-1 Shinmachi, Hirakatashi 573-1010, Osaka, Japan.ORCID 0000-0003-3295-0273
Satoaki NakamuraDepartment of Radiology, Kansai Medical University Hospital, 2-5-1 Shinmachi, Hirakatashi 573-1010, Osaka, Japan.
Masaaki TerashimaMedical Oncology, Izumi City General Medical Center, 4-5-1 Wakechou, Izumishi 594-0073, Osaka, Japan.
Hiroshige YoshiokaDepartment of Thoracic Oncology, Kansai Medical University Hospital, 2-5-1 Shinmachi, Hirakatashi 573-1010, Osaka, Japan.ORCID 0000-0001-7724-0481
Masahiro FukuokaMedical Oncology, Izumi City General Medical Center, 4-5-1 Wakechou, Izumishi 594-0073, Osaka, Japan.
Takayasu KurataDepartment of Thoracic Oncology, Kansai Medical University Hospital, 2-5-1 Shinmachi, Hirakatashi 573-1010, Osaka, Japan.ORCID 0000-0003-4123-3567

Funding

Ono Pharmaceutical Company, LTD None
6 · The paper itself

Abstract

Despite advancements in diagnosing and treating non-small cell lung cancer (NSCLC), the prognosis remains poor. Immune checkpoint inhibitors have shown promise in enhancing survival rates. Therefore, this study aimed to investigate the safety of nivolumab administration with concurrent chemoradiation therapy (CCRT) in patients with unresectable locally advanced NSCLC. Twelve patients with unresectable locally advanced NSCLC at Kansai Medical University Hospital and Izumi City General Medical Center were enrolled from May 2018 to September 2020. They received nivolumab (360 mg) tri-weekly twice, weekly carboplatin (AUC 2 min × mg/mL) and paclitaxel (40 mg/m

Indexed as

chemoradiotherapyfeasibility studynivolumabunresectable locally advanced non-small cell lung cancer

Identifiers

PMID39335099
PMCPMC11430718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.